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1. Introduction 
Anal cancer is a rare tumor, whose incidence has increased in recent years. Its incidence is 
approximately 1.5 / 100,000 in the general population (Jemal et al, 2009, Siegel et al, 2011). 
Historically anal cancer is more common in women, however the incidence in men has been 
increasing, especially among those who practice anal sex with men (MSM).  
Among the risk factors are human papillomavirus (HPV), smoking, immunosuppression 
and anal sex (Uronis et al, 2007) 
The most common anal cancer is the squamous cell carcinoma. It may be keratinized or non-
keratinized. Adenocarcinoma may occur, however, it resembles the lower rectal cancer and 
should follow its principles of treatment. (Nivatvongs, 2006) According to the World Health 
Organization (WHO), approximately 80% of tumors of the anal canal are squamous cell type 
and these are divided in squamous cell carcinoma tumors, basaloid (cloacogenic) and 
mucoepidermoid. In this classification of tumors of the anal region, WHO considers the anal 
verge, anal canal, the anal transition zone and the rectal type mucosae of the anal canal. 
Therefore, other histological types of tumors can arise in the anal canal. Adenocarcinomas 
may originate in the rectal type mucosae in the anal canal and in the path of a long evolution 
anal fistula or in the epithelium of the anal glands. Other tumors may be lymphoma, 
melanoma, Kaposi's sarcoma, Bowen's disease and Paget's disease. (Table 1) 
 
HISTOLOGICAL TYPE ORIGIN 
SQUAMOUS CELL CARCINOMA  SKIN AND ANAL VERGE 
ADENOCARCINOMA 
RECTAL TYPE MUCOSAE 
ANAL GLANDS 
FISTULA’S PATH 
LYMPHOMAS ANAL CANAL 
MELANOMA 
ANAL CANAL 
ANAL VERGE 
KAPOSI 
ANAL CANAL  
ANAL VERGE 
BOWEN ANAL VERGE 
PAGET ANAL VERGE 
Table 1. Histological types of malignant tumors of the anal canal and its origin in the 
anorectal region. 
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The human papilloma virus (HPV) belongs to Papillomavirus genus of the family 
Papillomaviridae. It causes the lesion called condyloma acuminata (from the greek 
“Kondilus”, that means rounded tumor, and the latin “acuminare” meaning make sharp). 
Infection by HPV is a sexually transmitted viral disease most common in sexually active 
population. According to the Centers for Disease Control and Prevention (CDC) between 
1966 and 1981 there was a 500% increase in the incidence of condyloma acuminata. In 1996 it 
was estimated that the incidence per year was 500 thousand to 1 million new cases and 25% 
of the population was infected. Therefore, the Human Papilloma Virus (HPV) is the most 
common sexually transmitted disease. Its association with cervical cancer is well 
established. However, their role in anal cancer as the primary cause, not just as a cofactor, is 
being increasingly accepted. There are several serotypes of HPV, with different risks of 
inducing cancer.  
2. Anatomy of the anal canal  
The anal canal is a small area that extends from the anal verge to the rectal mucosa, 
bypassing the dentate line. It is a complex area that has different histological features. The 
diversity of cells in this region is wide for being the junction of embryonic layers. According 
to World Health Organization (WHO), the anal canal is defined as the terminal part of the 
large intestine, beginning at the upper surface of the anorectal ring and passing through the 
pelvic floor at the anus. The lower part extends from the dentate line and downwards to the 
anal verge. This was therefore the surgical anal canal. The lateral limit is 5 to 6 cm from anal 
verge. (Nivatvongs, 2006). The skin of the anal margin consists of a keratinized squamous 
epithelium and eccrine and apocrine glands and other appendages such as hair follicles and 
may thus be compromised for any condition that affects the skin itself and its structures 
such as malignant tumors.  
Lymphatic drainage above the dentate line is for the lymphatic chain of the lower 
mesenteric vessels passing trough the lymphatic chain of the superior rectal vessels. 
Lymphatic drainage below the dentate line runs to the inguinal lymph nodes.  
The anal canal represents the end of the squamous mucosa and the beginning of a transition 
zone for non-squamous mucosa. There is a transition from squamous epithelium to an 
immature epithelium, in which a squamous epithelium overlaps a columnar epithelium, to a 
squamous metaplastic area of tissue that occurs above the dentate line, which has a 
columnar epithelium.  
Therefore tumors of this region may be keratinized or non-keratinized, but with similar 
biology and prognosis. 
3. Human Papilloma Virus (HPV) 
HPV is a sexually transmitted disease of high incidence. HPV is a DNA Papilloma virus 
with an 8-kilobase genome. Systematic reviews of the literature showed a prevalence of 
genital HPV infection ranging from 1.3% to 72.9%. These variations are due to different 
study populations and different diagnostic methods. (Dietz et al. 2011, Uronis et al. 2007, 
Bean et al. 2009, Chin Hong et al. 2004, Darragh et al. 2011, Fox 2006, Giuliano et al. 2010)  
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In most patients, the virus is rapidly recognized by the immune system, with only 1% of 
patients developing clinical symptoms of infection (anal warts). The estimated prevalence of 
subclinical infection varies between 10 and 46% (Welton et al. 2004) 
Transmission of the virus is not entirely preventable by using condoms and sexual 
abstinence is the only way to effective prevention. The virus can remain in the secretion at 
the base of the penis and scrotum, making the condoms ineffective. 
Chronic infection occurs in a minority of patients who are exposed to HPV. For this to occur 
the virus must gain access to the basal and parabasal cells of the anorectal transition zone 
through erosion or disruption of normal mucosal barrier, which can occur in anal sex, 
anorectal trauma from other causes, or concomitant presence of infections of other sexually 
transmitted diseases. There are more than 80 different subtypes of HPV. Among them, at 
least 23 have potential for infection of the anogenital mucosa. Each subtype has a different 
potential to induce malignancy. HPV 6 and 11 serotypes are most associated with genital 
warts and have less oncogenic potential. Already serotypes 16,18,31, 33, 35, 39, 45, 50, 51, 53, 
56, 58, 59 and 68 are most commonly identified in high-grade dysplasia or carcinoma 
(Uronis et al, 2007). The serotype can be evidenced by specific test for DNA. Serotype 16 is 
the most prevalent and associated with 70% of cases of anal cancer. 
Anal warts are a benign condition not associated with mortality. However, it is a disease 
that causes psychosocial stress, shame and embarrassment. The incubation period is 3 weeks 
to 8 months; most of them develop 2-3 months after infection with HPV. Over 90% of warts 
are caused by serotypes 6 and 11, however approximately one third achieve co-infection 
with oncogenic serotypes. 
Several cancers are attributed to HPV infection. These include cancers of the cervix, vagina, 
vulva, penis, oral cavity, head and neck and anal canal. The two most common HPV-
associated cancers are anal cancer and cervical cancer. Both occur in the mucous epithelium, 
while anal cancer also occurs in the perianal keratinized epithelium. 
Several epidemiological studies have assessed the association between HPV and anal CA. In 
a recent study, DURAES and SOUSA showed a strong correlation between CA and anal 
HPV in Brazil. (Duraes & Sousa, 2010) 
Anal sex is the major risk factor for HPV infection, but heterosexual men who did not have 
sex with men may present with HPV infection. 
The prevalence of HPV infection in men who have sex with men (MSM) HIV negative 
reaches 57% (Chin-Hong et al, 2004) 
4. Anal cancer 
Anal cancer accounts for approximately 2.6% of carcinomas of the large intestine. Its 
incidence is increasing in the United States, Europe and South America. The American 
incidence has been increasing over the past 40 years. In 2003, there was an estimated 4,000 
new cases in the United States. In 2007, about 4650 new cases, and in 2009 the number was 
estimated to be 5,290 new cases (2100 men and 3190 women). In 2011 the figure was 5820 
new cases (2140 men and 3680 women) (Siegel et al, 2011). 
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The incidence rate is higher in women in all age groups, however the incidence in men has 
increased. The incidence rates are 1.4 per 100,000 in men and 1.7 per 100,000 in women. 
Anal cancer was initially associated with chronic inflammatory conditions such as Crohn's 
disease. Then viral genital infections were associated. HPV infection, with or without 
immune compromise was seen as the main risk factor for the development of anal dysplasia, 
which is the precursor lesion of anal cancer.  
Other associated risk factors are anal sex, number of sexual partners, smoking and history of 
anal warts. For women the history of vulvar intraepithelial neoplasia and high-grade 
cervical or vulvar cancer are considered risk factors. Imunossupressed post-transplant 
patients are also considered high risk. 
The populations most at risk for anal cancer are men who have sex with men (MSM), 
regardless of HIV infection. Other risk groups are imunossupressed individuals and HIV 
positive. 
Although it is a rare cancer, the incidence in men who have sex with men (MSM) HIV-
positive has been increasing, especially in those using antiretroviral therapies. The incidence 
of anal cancer in HIV-negative MSM is approximately 35 per 100000. In the HIV-positive 
MSM the incidence range from 42 to 137 per 100,000 per year. 
Symptoms include rectal bleeding (in half of patients), pain, and rectal mass sensation. 20% 
of patients have no symptoms. Cancer of the anal canal extends to the rectum or perianal 
skin in half of the cases. 
Anal cancer can give metastases via the lymphatic system, and less frequently, can be 
hematogenous. Anal cancer below the dentate line is at risk of metastasis to the inguinal and 
femoral nodes. Above the dentate line the risk of metastasis is to the perirectal lymph nodes. 
The diagnosis in early stage is possible by clinical evaluation by detecting the presence of a 
papular nodule or tumor in the anal canal, of varying size and hardness, which may be fixed 
or not the muscle planes. You can often see a fissure at the anal inspection, presenting itself as 
an ulcerated lesion with raised borders and irregular, hard, lumpy, very painful that easily 
bleeds when touched. Proctological examination for evaluation and biopsy is often only 
possible with the anesthetized patient. In advanced disease, vegetative ulcers lesions are often 
observed, advancing extensively to the perineum, vulva, vagina and sacrococigeal region. 
These advanced lesions can cause pain to urinate, evacuate or even walk. The not diagnosed, 
untreated disease evolves compromising the anal sphincter apparatus and leads to progressive 
stenosis of the anal canal and can result in fecal incontinence and production of foul-smelling 
discharge. The differential diagnosis should be done with various anorectal diseases, and the 
anal fissure disease that requires further attention. The typical pain of the fissure that occurs 
after the evacuation can also occur in early carcinoma, but with the progression of the disease 
the pain becomes continuous, persistent and almost unbearable. The atypical location, outside 
the median line and above the dentate line is important data to rule out idiopathic anal fissure.  
5. Anal cancer staging 
The staging for anal cancer is done through the TNM system (tumor, node, metastasis). The 
TNM is based on the anatomical extent, where T refers to the primary tumor, N refers to 
lymph node metastases, and M refers to the presence or absence of distant metastases. 
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As for the T rating: 
Tis or carcinoma in situ. 
T1: Tumor measures 2 cm or less. 
T2: Tumor is between 2 and 5 cm. 
T3: Tumor is larger than 5 cm. 
T4: Tumor of any size invading adjacent structures such as the urethra, vagina or bladder. 
Regarding the classification N: 
N0: No lymph node metastases 
N1: Metastasis in perirectal lymph nodes 
N2: Unilateral metastasis in inguinal lymph nodes or unilateral internal iliac nodes 
N3: Bilateral metastasis in inguinal lymph nodes or bilateral internal iliac 
As for the M rating: 
M0: No distant metastases. 
M1: Distant metastases. 
6. Staging 
The staging of anal carcinoma requires a digital rectal exam, a CT scan of chest, abdomen 
and pelvis. In any suspicion of affected lymph nodes, fine needle aspiration biopsy should 
be performed. The use of PET CT is not well established. 
 
Stage T N M 
Stage 0 Tis N0 M0 
Stage I T1 N0 M0 
Stage II T2 N0 M0 
Stage II T3 N0 M0 
Stage III A T1, T2, T3 N1 M0 
Stage III A T4 N1 M0 
Stage III B T4 N1 M0 
Stage III B Any T N2, N3 M0 
Stage IV Any T Any N M1 
Table 2. TNM Staging for Anal Cancer. 
The gynecological examination, including cervical cancer screening is recommended for 
women with anal cancer. The HIV test is recommended. In case of positivity, CD4 levels 
should be evaluated. 
The endoanal ultrasound, especially with three-dimensional view, helps in assessing the 
depth of tumor invasion and involvement of adjacent nodes. 
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7. Natural history of high grade squamous intraepithelial lesions and anal 
cancer 
Much of the information about anal cancer, because of its low incidence, is extrapolated 
from cervical cancer. This extrapolation is due to the great similarity between the histology 
and histopathology of the tissues involved. 
HPV can lead to formation of anal warts, low-grade squamous intraepithelial lesion (LSIL), 
high-grade squamous intraepithelial lesion (HSIL) and cancer. The mechanisms of 
progression of lesions in the anal canal are not fully elucidated. (Ortoski & Kell, 2011) 
The development of squamous cell carcinoma of the anus appears to be similar to squamous 
cell carcinoma of the cervix, which means, transition from anal low-grade squamous 
intraepithelial lesions (LSIL) for anal high-grade squamous intraepithelial lesions (HSIL) 
and then to squamous cell carcinoma. 
Genital warts are typically caused by serotypes of HPV that are at low risk for induction of 
carcinoma. LSIL can be identified in association with warts, especially those flat lesions. The 
presence of concomitant condylomatous lesions and HSIL is uncommon in 
immunocompetent patients. However, in immunocompromised patients, HSIL is usually 
found in association with genital warts. These patients have infections with multiple HPV 
types, compared with immunocompetent patients, which may explain this finding. 
Both the cervix and the anal canal have regions of metaplasia replacing glandular 
epithelium with squamous epithelium. HPV infects the basal cells causing an interruption in 
the cycle of cell differentiation and maturation of precursors leading to the development of 
cancer. 
The virus interferes with the mechanisms of the cell cycle, resulting in cell proliferation 
during latency. There is a loss of cell cycle inhibition through the action of two viral genes 
E6 and E7. The E7 interferes with the cell cycle, allowing the cell to progress from G1 to S 
phase. The events caused by E7 are not sufficient for malignant transformation. 
Accumulated genetic errors in cell replication are necessary for malignant transformation, 
which is consistent with the fact that chronic infection with HPV is necessary for the onset of 
cancer. The accumulation of genetic errors is facilitated by E6. This protein binds to p53, 
leading to degradation it. The p53 protein is a protein important for regulating the cell cycle 
that leads to apoptosis of cells with accumulated genetic errors, preventing replication 
errors. 
Taking into account the high incidence of HSIL in HIV-positive MSM, it appears that only a 
minority will progress to cancer, but it is not possible to predict which lesions will progress, 
regress or persist. 
The prevalence of high-grade squamous intraepithelial lesions (HSIL) confirmed by biopsy 
is very high: approximately 50% of homosexual HIV positive and 25% of HIV negative 
MSM. 
High-grade anal dysplasia in HIV-positive men can progress to invasive cancer within a 
short period of time (Kreuter et al, 2010) 
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The role of HIV infection in anal cancer has not been elucidated. Population studies failed to 
show a correlation, including a study by the authors of epidemiological data in Brazil. The 
use of antiretroviral therapy and increased survival of HIV-positive can change this data in 
the future. 
8. Histopathology of intraepithelial lesions and anal cancer  
The classification follows the same cytological classification of cervical cytology: 
ASCUS: Atypical Squamous Cells Undetermined Significance 
ASCH: Atypical Squamous Cells suspicious for HSIL 
ASIL: Atypical Squamous intraepithelial Lesion 
LSIL: Low-grade Squamous intraepithelial Lesion 
HSIL: High-grade Squamous intraepithelial Lesion 
SCC: Squamous Cell Carcinoma 
Histological classification terminology follows below: 
AIN: Anal intraepithelial neoplasia 
AIN 1: Mild dysplasia 
AIN 2: Moderate dysplasia 
AIN 3: Severe dysplasia / carcinoma in situ 
Invasive Anal Carcinoma 
The LSIL corresponds to an AIN. The HSIL corresponds to AIN2, carcinoma in situ or 
AIN3. The ASCUS and ASCH don`t have all the features of HSIL, but are not classified as 
benign. 
Anal cancer is classified by degree of differentiation and histogenesis. 
There are several microscopic appearances, including large-cell keratinizing, large-cell and 
basaloid nonkeratinizing. The term cloacogênic carcinoma is used to basaloid tumors and 
forms of non-keratinized squamous cell carcinoma. 
Although squamous intraepithelial lesions and squamous cell carcinoma lesions are most 
often found, the distinction between squamous cell carcinoma poorly differentiated and 
other lesions such as lymphoma and melanoma can be difficult, sometimes requiring use of 
immunohistochemistry. 
9. Screening 
The screening performed in cervical cancer led to a decrease in the incidence of cancer with 
early detection of pre malignant lesions. Taking into account the similarity between anal 
cancer and cervical cancer, there are proposals for population screening for anal cancer. 
(Darragh & Winkler, 2011) 
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The goal of screening is to identify and treat cancer and early high grade squamous 
intraepithelial lesion (HSIL). As in cervical cancer, anal cytology is classified as atypical 
squamous cells of undetermined significance (ASCUS), atypical squamous cells suspicious 
for HSIL (ASCH), low grade squamous intraepithelial lesion (LSIL), high-grade squamous 
intraepithelial lesion (HSIL) or cancer. 
The introduction of population screening programs for high-grade squamous intraepithelial 
lesion (HSIL) is limited by little evidence that interventions alter the natural history of HPV 
infection and progression to anal cancer. No randomized clinical trial was conducted to 
validate any form of screening for anal cancer. In specific groups of patients who have an 
increased incidence, as men who have sex with men (MSM), the screening should be 
performed. In this group of patients the incidence of cancer is comparable with cervical 
cancer where screening is routinely performed. 
The simplest screening test is the digital anal-rectal exam. The lesions would be palpable, 
even in the absence of clinical symptoms. This technique, although inexpensive, is not 
commonly used.  
Anal cytology has been used since 2005, but there is still a difficulty in their interpretation. 
The purpose of anal cytology is to take samples of all the anal canal, including the 
transformation zone. Samples of cells are collected by a swab inserted into the anal canal 
through the dentate line, thus allowing the collection of samples of the distal rectal wall. The 
cytology identifies intraepithelial lesions as LSIL, HSIL, and cancer in situ. The differential 
diagnosis of HSIL and cancer (early invasive ASCC) is difficult. Therefore biopsy for 
diagnostic confirmation is necessary (Bean & Chhieng, 2009).  
A cost-effectiveness proposal is anal cytology testing every 1 to 2 years in HIV positive and 
men who have sex with men (MSM) HIV negative (Lam et al, 2011).  
The hybrid capture test can complement cytology, with the identification of serotypes of 
HPV anal cancer precursors. 
Taking into account the similarities with cervical cancer, was introduced a form of anal 
colposcopy, called high-resolution anoscopy (HRA). The HRA is indicated in those 
patients in whom cytology showed ASCUS, ASCH, LSIL or HSIL. Similar to colposcopy, 
adequate equipment and training are needed. An anoscope is introduced to 
approximately 2 cm from the anus, allowing visualization of the dentate line and the 
transitional zone. It is applied a solution of 3% acetic acid. Using a gynecological standard 
colposcope with a light source and lens with a magnification of 20 to 30 times, the 
examiner tries to identify areas of dysplasia. The Lugol iodine solution is then applied 
revealing dysplastic areas. Vascular changes such as neovascularization, venous 
interruption, changes in venous caliber are also suggestive of malignant tissues. Guided 
biopsies are performed in these abnormal areas. A biopsy is the gold standard for 
identification of squamous intraepithelial lesions. 
10. Treatment of high grade squamous intraepithelial lesions (HSIL) 
There is ample evidence that HSIL is the precursor to anal cancer, although the rate of 
progression to cancer is unknown. 
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Several treatments are recommended for the HSIL, which is a benign lesion and it takes a 
long time for malignant transformation. 
The use of electrocautery has the advantage of being easily accessible in various surgical 
environments. It is less morbid than surgical excision, especially in extensive lesions. A 
disadvantage is that it doesn`t allows the histopathology of the lesion, and may not identify 
an invasive carcinoma. The recurrence with use of electrocautery is 79% in 12 months, with 
100% risk at 50 months in HIV positive men. The use of high-resolution anoscopy 
contributes to the identification of lesions to be cleared. 
A complete excision of the anal transition zone is possible, however may impair continence, 
being reserved for early carcinomas. Depending on the size of the lesion, the use of flaps 
may be necessary for the reconstruction of the skin. Surveillance anoscopy with high 
resolution is recommended. 
In well-defined lesion with the use of Infra-Red Coagulation (IRC) can be attempted. 
Topical agents may be tried. Imiquimod is an immune response modifier with potent 
antiviral and antitumor activity. It has been used to treat warts, basal cell carcinoma, vulvar 
intraepithelial neoplasia, squamous cell carcinomas of the skin, herpes and others. The 
application of imiquimod is safe, effective and promising in the treatment of HSIL. Topic 5% 
5-fluorouracil (5FU) may be used in combination with imiquimod. 
Another topical agent cidofovir is promising. This is a 1% gel used 5 days a week for 6 
weeks for effective control of HPV. When used in intraepithelial lesions, this was proven 
effective in several cases (Snoek et al, 2000). 
Liquid nitrogen, as well as cryotherapy, may be used. 
11. Treatment of anal cancer 
Prevention and early detection of anal cancer is of paramount importance due to the impact 
on survival. Patients with localized cancer of the anus have a five-year survival rate of 
approximately 80%. Patients with metastases have a survival rate of 30%. 
The radio chemotherapy is the gold standard for treatment of anal cancer. Surgical 
treatment may be performed. 
Surgical excision may be used in early carcinomas, well differentiated that did not exceed 
the submucosa. This type of treatment has a recurrence rate of 20 to 78% with a 5-year 
survival from 45 to 85%. This treatment should be used in selected cases. Mobile lesions 
smaller than 2 cm are candidates for this treatment modality. 
The abdomino-perineal amputation was the most widely used form of treatment in the past. 
Although this treatment is aggressive, the results are not encouraging. The recurrence is 27% 
to 50% and 5-year survival ranges from 24% to 62% with a mortality rate of 2-6%. Currently, 
the abdomino-perineal amputation is reserved for those patients who do not tolerate radio 
chemotherapy. This operation is also indicated in cases of treatment failure by radio 
chemotherapy. 
Treatment with radio chemotherapy was initiated in 1974 by Nigro et al. The treatment 
involves the use of radiotherapy combined with 5-fluorouracil (5 FU) and mitomycin C. This 
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form of treatment proposed by Nigro was used initially as a neoadjuvant regimen for 
abdomino-perineal amputation. After 6 weeks the patients underwent operation. Nigro 
noted that a number of surgical specimens showed complete pathological response, which 
led him to propose exclusive radio chemotherapy treatment. Other studies have been 
performed comparing radiotherapy alone with radio chemotherapy, showing the 
superiority of radio chemotherapy. Studies have also shown a better therapeutic response 
with the use of mitomycin C associated with radiotherapy and 5 FU, despite its greater 
toxicity. 
The radio chemotherapy has complications such as dermatitis, mucositis, diarrhea, fecal 
incontinence, bone marrow depression, cystitis, enteritis and vascular involvement. 
In cases of failure to treat with radio chemotherapy, new sessions of radiation or surgical 
treatment of redemption can be realized. 
Brachytherapy is used as an alternative to radiotherapy with the aim of preserving adjacent 
organs from radiation. It is still in studies to date. 
HIV patients are treated with a lower dose of radio chemotherapy than for HIV-negative 
patients, due to increased risks of toxicity in these patients. 
Metastatic disease appears in 10 to 17% of patients treated with radio chemotherapy. The 
most common site of metastasis is the liver. Treatment includes chemotherapy 5 FU 
combined with cisplatin, carboplatin, doxorubicin and semustine. 
12. Prognosis 
The 5-year survival for anal cancer is 80.1% for localized anal cancer, 60.7% for regional 
disease, and 29.4% for metastatic disease. The nodal involvement, T stage, and male are 
predictors of distant metastases, high rate of colostomy, and a worse survival with the use of 
radio chemotherapy. HIV-positive patients with low CD4 counts and high viral load has 
worse prognosis. (Abbas, 2010) 
13. HPV vaccination 
In 2006, the first U.S. FDA prophylactic vaccine against HPV was approved. The 
quadrivalent vaccine has proved effective in preventing infection against HPV 16, 18, 6 and 
11 in healthy women. The bivalent vaccine is effective against serotypes 16 and 18. The 
vaccine is recommended for women from 11 to 26 years of age before the onset of sexual 
activity. 
As for male vaccination, is still controversial. Among the benefits related to the vaccine in 
males, is prevention of penile cancer, beyond the indirect benefits that women have with 
male vaccination. In countries like the United States, only 37% of eligible women received 
the vaccine in 2008. Vaccinating men might increase protection against HPV in both men 
and women. There is a recommendation to vaccinate men from 9 to 26 years of age. 
 Although the vaccine is effective in preventing cervical HPV infection, is still uncertain 
protection of their anal infection. Studies show the prevention of intraepithelial neoplasia 
type 2 and 3. 
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There are doubts about vaccination of HIV-positive, since the vaccine response in 
immunocompromised patients is uncertain. (Anderson, 2009) 
14. Conclusion 
Anal cancer, particularly squamous cell carcinoma is a disease whose incidence is 
increasing. Prevention and early diagnosis is the key to reducing mortality caused by the 
disease. The prevalence of HPV is currently too high and its prevention and detection 
constitutes a major medical challenge. HPV has an important role in the pathogenesis of 
anal carcinoma, especially in immunocompromised patients. Risk group subjects should 
take precautions. The HPV vaccine can reduce the incidence of disease in the near future 
and contribute significantly in reducing mortality from anal cancer. 
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